Applied Therapeutics, Inc. (APLT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. John H. Johnson | Executive Chairman | 378.84k | -- | 1958 |
| Mr. Les D. Funtleyder | Interm CEO, CFO, Principal Financial Officer & Director | 768.85k | -- | 1970 |
| Mr. Corwin Dale Hooks | Chief Commercial Officer | 636.74k | -- | 1967 |
| Mr. Constantine Chinoporos | COO & Chief Business Officer | -- | -- | 1966 |
| Ms. Catherine Thorpe | Interim Chief Accounting Officer | -- | -- | 1964 |
| Dr. Riccardo Perfetti M.D., Ph.D. | Chief Medical Officer | 860.76k | -- | 1960 |
| Ms. Reena Thomas Colacot | Head of Quality | -- | -- | -- |
| Dr. Todd F. Baumgartner M.D., M.P.H. | Chief Regulatory Officer | -- | -- | -- |
Applied Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 36
Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Corporate Governance
Upcoming Events
August 5, 2025 at 12:30 PM UTC - August 11, 2025 at 12:30 PM UTC
Applied Therapeutics, Inc. Earnings Date